Back to mobile site
Get it on Google Play

Scynexis completes Phase 1 IV study of antifungal SCY-247

October 22, 2026 8:01 AM EDT Send to a Friend
Scynexis (NASDAQ: SCYX) announced topline results from its Phase 1 single and multiple ascending dose trial of the intravenous formulation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login